Evidence map›Paper›PMID 38929562›Full record

ReviewMedicina (Kaunas, Lithuania)2024

The Complement System as a Therapeutic Target in Retinal Disease.

Joshua Ong, Arman Zarnegar, Amrish Selvam, Matthew Driban, Jay Chhablani

Abstract readReview
In one paragraph

Review in Medicina (Kaunas, Lithuania), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Joshua OngDepartment of Ophthalmology and Visual Sciences, University of Michigan Kellogg Eye Center, Ann Arbor, MI 48105, USA.ORCID 0000-0003-4860-827X
Arman ZarnegarDepartment of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Amrish SelvamDepartment of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Matthew DribanDepartment of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.ORCID 0000-0003-3573-3290
Jay ChhablaniDepartment of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.ORCID 0000-0003-1772-3558

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The complement cascade is a vital system in the human body's defense against pathogens. During the natural aging process, it has been observed that this system is imperative for ensuring the integrity and homeostasis of the retina. While this system is critical for proper host defense and retinal integrity, it has also been found that dysregulation of this system may lead to certain retinal pathologies, including geographic atrophy and diabetic retinopathy. Targeting components of the complement system for retinal diseases has been an area of interest, and in vivo, ex vivo, and clinical trials have been conducted in this area. Following clinical trials, medications targeting the complement system for retinal disease have also become available. In this manuscript, we discuss the pathophysiology of complement dysfunction in the retina and specific pathologies. We then describe the results of cellular, animal, and clinical studies targeting the complement system for retinal diseases. We then provide an overview of complement inhibitors that have been approved by the Food and Drug Administration (FDA) for geographic atrophy. The complement system in retinal diseases continues to serve as an emerging therapeutic target, and further research in this field will provide additional insights into the mechanisms and considerations for treatment of retinal pathologies.

Indexed as

Complement System ProteinsRetinal DiseasesAnimalsComplement Inactivating AgentsDiabetic RetinopathyHumansRetinaComplement Inactivating AgentsComplement System Proteinsage-related macular degenerationchoroidcomplement systemretinal therapy

Identifiers

PMID38929562
PMCPMC11205777

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.